Abstract:Background: In metastatic breast cancer (MBC), [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [18F]FDG uptake in corresponding metastases. Patients and Methods: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [18F]FDG uptake was expressed as maximum standardized uptake value (SUVmax) and results were expressed as geometric means. Results: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥20% were correlated with higher [18F]FDG uptake (estimated geometric mean SUVmax 10.0 and 8.8, respectively; p = 0.0064 and p = 0.014). [18F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUVmax 6.8 and 10.0, respectively; p = 0.0058). Although [18F]FDG uptake was lower in invasive lobular carcinoma (n = 31) than invasive carcinoma NST (n = 146) (estimated geometric mean SUVmax 5.8 versus 7.8; p = 0.014), the metastasis detection rate was similar. Conclusions: [18F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [18F]FDG uptake, [18F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332).

What problem does this paper attempt to address?

This paper attempts to address the correlation between breast cancer histopathological prognostic features and [18F]FDG uptake in corresponding metastatic lesions in newly diagnosed metastatic breast cancer (MBC). Specifically, the researchers aim to determine whether these imaging features are related to the tumor's histopathological characteristics (such as hormone receptor status, HER2 status, Ki-67 proliferation index, and histological type) by evaluating the performance of [18F]FDG-PET/CT in different subtypes of metastatic breast cancer. ### Research Background - **Metastatic Breast Cancer (MBC)**: One of the most common female malignancies, [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) is used for staging. - **[18F]FDG-PET/CT**: Can detect more bone lesions and provide information on metabolic activity. Cancer cells usually have higher metabolic activity, thus showing higher glucose uptake. - **Histopathological Features**: Include hormone receptors (ER, PR), HER2 status, Ki-67 proliferation index, and histological type, which significantly impact the tumor's biological behavior and treatment options. ### Research Objectives - **Evaluate Correlation**: The researchers aim to assess the correlation between breast cancer histopathological features and [18F]FDG uptake in corresponding metastatic lesions. - **Clinical Application**: To explore the value of [18F]FDG-PET/CT in different subtypes of metastatic breast cancer and its relationship with histopathological features to guide clinical decision-making. ### Main Findings - **HER2 Positive**: HER2 positive metastatic lesions show higher [18F]FDG uptake. - **Ki-67 Proliferation Index**: Tumors with Ki-67 ≥ 20% show higher [18F]FDG uptake. - **Histological Type**: Invasive lobular carcinoma (ILC) has lower [18F]FDG uptake compared to invasive non-special type carcinoma (NST), but both have similar detection rates. - **Molecular Subtypes**: HER2 positive subtype has the highest [18F]FDG uptake, followed by triple-negative breast cancer (TNBC), with the lowest uptake in ER positive/HER2 negative subtype. ### Conclusion - **Complementary Role**: [18F]FDG-PET is an effective tool for detecting metastatic breast cancer, but histopathological features still need to be assessed through biopsy. Therefore, [18F]FDG-PET and biopsy are complementary in the staging of metastatic breast cancer. - **Clinical Significance**: The study supports the use of [18F]FDG-PET in different subtypes of metastatic breast cancer, especially in invasive lobular carcinoma, and that biopsy can be performed before or after [18F]FDG-PET without affecting uptake results. This study provides important reference data for the use of [18F]FDG-PET and histopathological assessment in clinical practice.

Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer